case_images: PMC6806250_01
case_images: PMC6806250_02
case_images: Chest X-ray scan revealed a tumor shadow in the right hilar area, an invasive shadow in the left middle and lower lung fields, and pleural effusion on both sides.
case_images: EXCLI-18-893-g-001.jpg
case_images: PMC6806250_02_EXCLI-18-893-g-001.jpg
case_images: F1
case_images: A chest X-ray (Figure 1(Fig. 1)) revealed a tumor shadow in the right hilar area, an invasive shadow in the left middle and lower lung fields, and pleural effusion on both sides. 
case_images: Computed tomography (CT) scan before administration of osimertinib. Primary lesions in the right middle and lower lobes, multiple cystic lesions in the lung field, and mild pneumothorax were observed in the right lung (a). Pleural effusion on both sides was observed (b).
case_images: EXCLI-18-893-g-002.jpg
case_images: PMC6806250_02_EXCLI-18-893-g-002.jpg
case_images: F2
case_images: PMC6806250_03
case_images: CT images after administration of osimertinib. Cavitation and decrease in size of the primary lesion were observed after 43 (a) and 81 days (b).
case_images: EXCLI-18-893-g-003.jpg
case_images: PMC6806250_03_EXCLI-18-893-g-003.jpg
case_images: F3
case_images: Respiratory state improved, and PS improved from 3 to 1, approximately 1 week from the introduction of osimertinib; cavitation and decrease in size of the primary lesion were observed via CT after 43 (Figure 3a(Fig. 3)) and 81 days (Figure 3b(Fig. 3)), respectively.